Phase 4 Chronic Kidney Disease Trial, Recruiting NCT06660524 Sponsor: China National Center for Cardiovascular Diseases Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Phase 4 Chronic Kidney Disease Trial, Recruiting

NCT06660524
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 50 years of age or older.
  • People who have been clearly diagnosed with degenerative (age-related wear and tear) heart valve disease, confirmed by ultrasound or medical history, with signs of calcium buildup in the valve — this includes cases ranging from no valve problems caused by the calcium, through to mild, moderate, or severe narrowing or leaking of the valve.
  • People whose kidneys are not working at full capacity, specifically with a kidney filtration rate below 60 mL/min as measured by a standard formula called CKD-EPI.
  • People with a higher-than-normal level of phosphorus in their blood (above 1.45 mmol/L or 4.5 mg/dL).

Who may not be able to join:

  • People who do not agree to sign the study's consent form.
  • People whose heart valve disease is caused by something other than age-related degeneration — for example, rheumatic heart disease or a heart valve problem present from birth — even if calcium buildup is present.
  • People whose valve condition has been assessed by a heart surgeon as needing surgery or a procedure, and where there are no medical reasons preventing that surgery or procedure.
  • People whose life expectancy is estimated to be less than one year.
  • People with abnormal parathyroid gland function (confirm with trial site).
  • People with kidney problems who are expected to need dialysis within the next six months.
  • People who have a malignant (cancerous) tumour.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 00-86-010-88398866

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
China National Center for Cardiovascular Diseases
Registry
ClinicalTrials.gov
Start date
1 March 2024
Est. completion
1 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The change of valve calcification score on CT scan from baseline to 1 year of treatment.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov